Chimerix (NASDAQ:CMRX) Coverage Initiated at StockNews.com

StockNews.com assumed coverage on shares of Chimerix (NASDAQ:CMRX) in a report released on Saturday morning. The firm issued a hold rating on the biopharmaceutical company’s stock.

Several other research firms also recently commented on CMRX. Wedbush reissued a “neutral” rating and issued a $8.55 target price (up previously from $7.00) on shares of Chimerix in a report on Wednesday, March 5th. Jefferies Financial Group reiterated a “hold” rating and issued a $8.50 price target (down previously from $10.00) on shares of Chimerix in a research note on Wednesday, March 5th. Finally, HC Wainwright restated a “neutral” rating and set a $8.55 price objective (down previously from $11.00) on shares of Chimerix in a research report on Wednesday, March 5th.

Chimerix Trading Up 0.1 %

Shares of CMRX opened at $8.47 on Friday. The business’s 50 day moving average is $4.94 and its 200 day moving average is $2.64. Chimerix has a 12-month low of $0.75 and a 12-month high of $8.48. The company has a market capitalization of $761.76 million, a PE ratio of -9.01 and a beta of 0.32.

Insider Activity at Chimerix

In other Chimerix news, CEO Michael T. Andriole sold 7,370 shares of the business’s stock in a transaction that occurred on Thursday, February 13th. The stock was sold at an average price of $4.52, for a total transaction of $33,312.40. Following the sale, the chief executive officer now directly owns 609,603 shares of the company’s stock, valued at $2,755,405.56. The trade was a 1.19 % decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which is available through this link. Insiders have sold a total of 20,760 shares of company stock valued at $91,175 over the last 90 days. 13.10% of the stock is owned by corporate insiders.

Institutional Investors Weigh In On Chimerix

Several institutional investors have recently modified their holdings of CMRX. Connor Clark & Lunn Investment Management Ltd. raised its holdings in Chimerix by 66.8% during the 3rd quarter. Connor Clark & Lunn Investment Management Ltd. now owns 344,712 shares of the biopharmaceutical company’s stock valued at $321,000 after buying an additional 138,098 shares during the period. Assenagon Asset Management S.A. increased its position in Chimerix by 154.8% during the fourth quarter. Assenagon Asset Management S.A. now owns 817,739 shares of the biopharmaceutical company’s stock valued at $2,846,000 after acquiring an additional 496,823 shares during the last quarter. Stoneridge Investment Partners LLC increased its position in Chimerix by 22.5% during the fourth quarter. Stoneridge Investment Partners LLC now owns 44,305 shares of the biopharmaceutical company’s stock valued at $154,000 after acquiring an additional 8,134 shares during the last quarter. Peapod Lane Capital LLC purchased a new stake in shares of Chimerix in the fourth quarter valued at $2,626,000. Finally, Valeo Financial Advisors LLC boosted its stake in shares of Chimerix by 78.8% during the 4th quarter. Valeo Financial Advisors LLC now owns 146,186 shares of the biopharmaceutical company’s stock worth $509,000 after purchasing an additional 64,420 shares during the period. 45.42% of the stock is owned by institutional investors.

Chimerix Company Profile

Chimerix, Inc, a biopharmaceutical company, develops medicines to improve and extend the lives of patients facing deadly diseases. Its pipeline products include ONC201 a program that is in Phase 3 clinical trial for treating patients with H3 K27M-mutant diffuse glioma, as well as in Phase 2 clinical trial for the treatment of rare neuroendocrine tumors; and ONC206, an imipridone, Dopamine Receptor D2 (DRD2) antagonist, and caseinolytic protease P (ClpP) agonist, which is in Phase 1 clinical trial for adult and pediatric patients with primary central nervous system tumors.